Sanofi could increase its Russian revenue by $50 million over next two years

As a result of the recent decision of the Russian Ministry of Health to allow the use of combined vaccines to vaccinate children at risk, French pharma major Sanofi and Russia’s Nanolek could increase their sales in Russia this year.

In the risk group, the Russian Ministry of Health includes prematurely born and small children, children with cancer, bowel anomalies, and so on, notes The Pharma Letter’s local correspondent.

Currently the production of Sanofi’s Pentaxim vaccine, which is a combined vaccine against five infections, is localized at the facilities of Nanolek, which is owned by Vladimir Khristenko, the son of the former Russian Minister of Industry and Trade Viktor Khristenko. The risk group currently includes about 420,000 children. It is planned that the companies will supply up to 2.4 million doses of vaccine for state needs during the next 1-1.5 years.